SMN2
39 programs · 39 companies
Programs
39
Companies
39
Active Trials
29
Targeting SMN2
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| NVO-6275 | Novo Nordisk | Phase 1 | SLE | |
| TAK-5300 | Takeda | Phase 1 | Endometrial CaCML | |
| GIL-2259 | Gilead Sciences | Approved | ET | |
| REG-647 | Regeneron | Preclinical | CLLNSCLC | |
| Olpafutibatinib | Immunocore | Approved | NMOSDMigraine | |
| EME-9677 | Emerald Health | Phase 1 | HCCWM | |
| SEO-IIT-219 | Seoul Natl Univ Hosp | Approved | Heart Failure | |
| MOR-7494 | MorphoSys (Novartis) | Phase 1 | EoEFSGS | |
| RIN-582 | Ring Ther | Phase 3 | IgAN | |
| Fixafutibatinib | Metsera | Preclinical | IgANNB | |
| Elraderotide | Kartos Ther | NDA/BLA | Endometrial Ca | |
| PCL-2819 | PharmaCielo | Preclinical | ObesitySCLC | |
| Polalemzoparlimab | ACLARION | Phase 3 | Prostate CaWM | |
| Polacagene | Palatin Technologies | Preclinical | MS | |
| Teralucimab | Marker Therapeutics | Approved | MDDADPKD | |
| Tixacagene | Cartesian Therapeutics | Preclinical | MDSMS | |
| Polalemzoparlimab | BioNova Pharma | Phase 1/2 | PsAHemophilia A | |
| Nidavorutinib | Medivation (Pfizer) | Phase 2 | NASHMyelofibrosis | |
| TRE-8359 | Treeline | Preclinical | PAHMS | |
| QUA-617 | Quanta Ther | Phase 1 | ACCSMA | |
| Doxaderotide | Ambys Med | Phase 3 | T2DThymoma | |
| STA-IIT-619 | Stanford Med | Approved | RSV | |
| EGR-8971 | Eagle Pharma | Phase 1 | AML | |
| Terazanubrutinib | Adamas (Supernus) | Preclinical | LGSHeart Failure | |
| Nirafotisoran | Arbor Bio | Preclinical | CKDET | |
| Poladerotide | Sana Biotech | Phase 1/2 | Cholangiocarcinoma | |
| Gozecilimab | Hanmi Pharma | Phase 2 | RSVET | |
| BIO-2612 | Biocon Biologics | Phase 1 | Celiac | |
| Geliderotide | Hikma Pharma | Phase 2 | CholangiocarcinomaLN | |
| Capiosocimab | Sprint Bio | Phase 1/2 | IPF | |
| Voxacapivasertib | Genkyotex (Calliditas) | Preclinical | ET | |
| Datorapivir | Merck KGaA | Phase 1 | Melanoma | |
| Zanurelsin | Bellus Health (GSK) | NDA/BLA | Pancreatic CaMDD | |
| CHA-IIT-901 | Charité Berlin | Approved | PAH | |
| PET-IIT-517 | Peter MacCallum | Phase 2 | PSP | |
| RGE-6554 | Repligen | Phase 1 | GISTEndometrial Ca | |
| Daranaritide | Zoetis | Phase 2/3 | Wet AMD | |
| Mavufotisoran | IDEXX Laboratories | Approved | RBHS | |
| Pemimavacamten | Arbutus Biopharma | Phase 2/3 | GIST |